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Background
The importance of developing of targeted drug delivery (TDD) systems:
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 TDD to tumor cells strategy is based on:
cell surface heterogeneity between normal cells and cancer cells
 Example: mitigating the selectivity problems of chemotherapy using high 
affinity biomolecular carriers such as antibodies
 There is a number of challenges to antibody–drug-conjugates efficient use
Background
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This study focus is to use much smaller carriers such as peptides
 peptide-drug-conjugates (PDCs)
 Specific for their target cells
 Do not induce outgrowth of  drug resistant cells
 Can reverse drug resistance and can deliver multi-drug payloads
 Conjugate the PDC to Gold nanoparticles overcomes their low stability
Background
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Gold nanoparticles (AuNPs)
 Favorable physico-chemical and safety properties
 Ease of synthesis
 Ligand modification is not necessary for chemiadsorption
on to the colloidal gold surface
 Can easily be conjugated to peptides, enzymes, DNA and small molecule drugs
 Improved pharmacokinetic and pharmacodynamics properties (when used as drug delivery
Systems)
 Lead to improved drug stability and reduced side effects
Background
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 The study hypothesize
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Methods
1-Cell culture
Normal cells (CC-2811 and CC2553)
3T3 mouse fibroblasts, human HL-60, NB4 and murine A20 leukemic cells
Mouse MOPC 315.BM cells
Murine heart and kidney cells
2-Removal of irrelevant phage clones by in vitro negative 
selection
3-Positive selection for A20 internalized phage peptides
4- Peptide synthesis
5- Specificity of peptide binding
6- Confocal microscopy
7- Synthesis of peptide–drug conjugates (PDC)
8- Synthesis of citrate-coated gold nanoparticles
9- PEG-6000 coated gold nanoparticles
10- Determination of loading efficiency of PDC on PEG AuNPs
11- Characterization of the PDC-PEG-AuNPs
Electrophoretic mobility assay and Morphology
13-Cell cytotoxicity assay
12- Stability of PDCs and PDC-coated PEG-GNPs
Chemostability and Biostability in liver homogenate
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Results
Identification of phage peptides specifically internalized by A20 cells
The absorbed library was then exposed to A20 cells (three rounds of selection)
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Identification of phage peptides specifically internalized by A20 cells
 Three clones, P-4, P-6 and P-8 were chosen for
further study
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Identification of phage peptides specifically internalized by A20 cells
 Binding capacity of the candidate peptides to the A20 cells
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Identification of phage peptides specifically internalized by A20 cells
 Confocal microscopy to compare peptide internalization into A20 cells
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Specificity of peptides for target and off-target cells
 Based on the results of previous section and peptide copy numbers
 P4 as a positive binder and P6 as a negative/weak binder
 Testing by flow cytometry the P4-FITC and P6-FITC for their binding at several  
concentrations to a panel of off-target lymphoid and myeloid cells:
 PBMC leukemic cells
 Murine MOPC 315.BM leukemic cells
 HL-60 and NB-4
• Mouse peripheral mononuclear cells (PBMC), human leukemic cell lines (HL-60(human acute promyelocytic
leukemia) and NB-4(human acute myeloid leukemia)
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Specificity of peptides for target and off-target cells
 Flow cytometry analysis of P4 and P6 peptides binding to off-target cells (PBMC) 
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Specificity of peptides for target and off-target cells
 Flow cytometry analysis of P4 and P6 peptides binding to off-target cells (MOPC 315.BM ) 
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Specificity of peptides for target and off-target cells
 Flow cytometry analysis of P4 and P6 peptides binding to off-target cells (NB-4)
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Specificity of peptides for target and off-target cells
 Flow cytometry analysis of P4 and P6 peptides binding to off-target cells (HL-60) 
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Cytotoxicity of free and peptide conjugated drugs
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 Cytotoxic effect of free drugs or P4-PDCs against target cells
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 Cytotoxic effect of free drugs or P4-PDCs against off-target cells
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Characterization of PDC-coated PEG-AuNPs
 Electrophoresis mobility assay
Figure S4: Electrophoretic mobility of AuNPs and PDC-AuNPs. In a 1.5% agarose gel in TAE running buffer
Lane 1: PEG-6000 AuNP
Lane 2: PEG-6000 AuNP-P4–Chlorambucil
Lane 3: PEG-6000 AuNP-P4–Melphalan
Lane 4: PEG-6000 AuNP P4-Bendamustine
Lane 5: PEG-6000 AuNP P6-Chlorambucil
Lane 6: PEG-6000 AuNP P6-Melphalan
Lane 7: PEG-6000 AuNP P6-Bendamustine
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Characterization of PDC-coated PEG-AuNPs
 Size and morphology of the PDC-PEG coated-Au nanoparticles (UV–VIS spectra analyses)
Figure S5: UV-VIS spectra in the range of 100-800nm of PEG-coated gold particles along and those 
non-covalently coated with peptide-drug-conjugates (PDCs)
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Characterization of PDC-coated PEG-AuNPs
 Size and morphology of the PDC-PEG coated-Au nanoparticles ( TEM analyses)
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 FTIR analyses of coated nanoparticles
Characterization of PDC-coated PEG-AuNPs
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Stability of P4-drug PDCs Vs stability of PDC coated PEG-AuNPs
Fig. 5 Stability of free PDCs and PDC-PEG-AuNPs. Chemostability was assessed by incubation the constructs in 0.01 M 
phosphate buffer solution pH 7.2 at 37 °C for different time intervals. The pDC integrity was analyzed by LC–MS
 Chemostability
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Stability of P4-drug PDCs Vs stability of PDC coated PEG-AuNPs
 Biostability
Fig. 5 Stability of free PDCs and PDC-PEG-AuNPs. Chemostability was assessed by incubation the constructs in 0.01 M 
phosphate buffer solution pH 7.2 at 37 °C for different time intervals. The pDC integrity was analyzed by LC–MS
 with half-lives ranging from 10.6 to 15.4 min.
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Cytotoxicity of PDC-coated PEG-AuNPs
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Discussion
• One of the main goals of targeted drug delivery systems:
• Reduce unwanted toxicities against healthy cells
• Phage display peptide technology is a powerful tool for the discovery of novel peptides
• The stock phage pool contains many clones with low affinity for candidate target receptors
• lead to a cross-reactive or non-specific binding that y competes with less abundant, but higher affinity 
clones
• Removal the library clones with affinity for cell surface components present on several types of off-
target cells 
• Increasing the possibility of fishing out clones that bind unique receptor(s) on the A20 target cells
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• Discovering several clones internalized by the target cells using the “absorbed phage library”
• The P4, P6 and P8 were chosen to study
• The suitability of P4 as a candidate drug carrier
• Testing the cytotoxic efficacy of three chemotherapeutics 
• Bendamustine enters the cell through the hOCT1 
• Chlorambucil is taken up by simple diffusion
• Melphalan is actively taken up by LAT1
Discussion
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Discussion
Conclusions
 PDCs by possessing a number of chemical, structural and biological advantages
 Improving the targeted delivery and efficacy of chemotherapeutic drugs 
 Limitation to their clinical application :the relatively short half-live 
 Pegylated-gold nanoparticles significantly extending PDC stability
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 The ability of AuNPs to extend the bioavailability of PDCs may:
 Developing prolonged targeted cancer cell treatment protocols
Future perspective
 Application of gold nanoparticles in oncology, including hematological cancers by 
combining with the potential for TDD of PDCs
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 Lead to slow release, targeted drug delivery systems
Thanks to your attention
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